US FTC files amended complaint against Hims&Hers

Hims & Hers Health (HIMS) reported a Q3 gross margin of 57% and reduced full-year adjusted EBITDA guidance to $257M-$277M, below analyst expectations. The stock fell 17% post-earnings, reflecting concerns about margin erosion and slower profitability growth. Analysts warn that reinvestment in AI and lower prices may delay earnings growth.

Five states joined the FTC's lawsuit against Hims & Hers, alleging privacy violations and deceptive billing practices. The FTC claims Hims shared health data with third parties and hid cancellation terms. Hims plans to defend itself, calling the new claims 'follow-on' allegations. The company recently reported a 49% revenue increase to $890 million but cut its 2026 profit outlook.

HIMS Health (HIMS) cut its 2026 adjusted core profit guidance to $257–$277 million and revenue guidance to $3.13–$3.15 billion, citing subscriber losses. Q4 revenue is expected at $875–$895 million, below estimates. The stock has fallen 41% year-to-date, with mixed retail investor sentiment.

The FTC and five additional states (Arizona, Florida, Nebraska, Ohio, Wisconsin) joined a complaint against Hims & Hers Health (HIMS), alleging the company shared patient health data with third-party advertisers. Utah and California were previously involved in the complaint. The case highlights potential privacy violations and regulatory risks for HIMS.

Five US states joined the FTC's lawsuit against Hims & Hers, alleging deceptive privacy and billing practices. The company is accused of sharing sensitive health data with third parties. Hims & Hers denies the claims and plans to defend itself. The case was filed in the US District Court for the Northern District of California.

Five US states (Arizona, Florida, Nebraska, Ohio, Wisconsin) joined the FTC's lawsuit against Hims & Hers Health, alleging deceptive and unlawful privacy practices. The amended complaint also includes Utah and California. The FTC filed the original lawsuit on Tuesday.